Active Pharmaceutical Ingredient Market: Global Industry Research Report 2020-2027 | Envisage Research
Envisage report cover

Active Pharmaceutical Ingredient Market - By Type of Drug (Prescription Drugs and Over-The-Counter (OTC) Drugs), By Type of Manufacturer (Captive API Manufacturers and Merchant API Manufacturers), By Type of Synthesis (Synthetic APIs Market, Biotech APIs Market), By Therapeutic Application (Communicable Diseases, Oncology, Diabetes, Cardiovascular Diseases, Pain Management, Respiratory Diseases, Other Therapeutic Applications) and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027

Published Date: May 2021

No. of Pages: 191

Status: Published

Report Code: EMR100370

The global active pharmaceutical ingredient market is estimated to reach USD 293 billion by 2027 from USD 187.76 billion in 2020, at a CAGR of 6.60 % during the forecast period. With advancements in healthcare infrastructure, healthcare spending has increased over time. This augmenting focus on healthcare spending positively influences the market for active pharmaceutical ingredients. The high adoption rate of generic drugs in developed and developing economies is fuelling the growth of the market. Another positive impact comes from the high demand for specialty medicines which is anticipated to escalate the spending in the pharmaceutical sector. Developed nations are expected to exhibit faster growth in these spending as compared to the developing economies on the back of factors such as the presence of adequate manufacturing units, transparent pricing, and higher spending power.

Outsourcing of R&D activities has emerged as a major trend in the market owing to reduced operational cost and enhanced operational efficiency in the value chain. Market participants are focused on possessing branded as well as unbranded generic drugs to maintain a balanced product portfolio. Asian nations such as India and China lead the market in the manufacturing of antibiotic Active Pharmaceutical Ingredient (API).

A higher generic adoption rate in developed countries driving global medicine spending and aiding greater access to improved, lifesaving healthcare services. The adoption of branded generic drugs is predicted to be higher in emerging economies such as China and India and generic drugs accounted for nearly 80% of the total drugs sold by value in these fast-growing nations in 2016. Rising use of specialty medicines is anticipated to grow the pharmaceutical spending worldwide with quicker growth in richer, developed nations as compared to their emerging counterparts. This is primarily because the former has adequate manufacturing units, a higher spending power, and greater emphasis on transparent pricing by assessing measuring effects on the population.

An intense focus on commercializing drugs and reducing operating costs by outsourcing R&D activities can improve the organizational efficiency substantially. Outsourcing at later stages of development through the appointment of strategic partners can potentially improve operational efficiencies throughout the value chain. A balanced portfolio approach goes a long way in expanding sales and simultaneously reducing risk. This could be by possessing branded generic drugs, branded drugs, and unbranded drugs within the same portfolio. In addition, clearly defined forward linkages in the supply chain can garner greater market share in different regions over the course of the forecast period.

The global APIs market is competitive in nature, with several big as well as emerging players. The prominent players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).

Pfizer is one of the leading players in the global API industry. The leading position of the company is majorly attributed to its exhaustive product portfolio. The company has a strong brand image, which gives it a competitive edge over other players. In order to remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies such as agreements, partnerships, collaborations, product approvals, and acquisitions. In accordance with this, in June 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (US), a leading biopharmaceutical company developing small molecule therapeutics.

Analyst Commentary

The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavourable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.
Based on the type of drug, the prescription drugs segment is expected to account for the largest share of the APIs market. The demand for drugs falling under this category has increased significantly in recent years due to the rising prevalence of target diseases. Additionally, the largest share of the prescription drugs segment can also be attributed to the increased focus of innovator companies on the development of specialty drugs and affordability of healthcare. The implementation of significant federal reforms to improve the affordability of healthcare, especially in the US, has expanded the consumption of both traditional and specialty drugs. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, particularly specialty drugs. All these factors are collectively responsible for the large share of this segment.

Based on type of manufacturer, the captive API manufacturers segment is expected to account for the largest share of the APIs market. This can be attributed to the fact that most big pharmaceutical companies possess their API manufacturing facilities and are vertically integrated across the pharmaceutical supply chain. Moreover, innovator companies prefer in-house manufacturing of innovative products to avail economic benefit and prevent technology leakage.

The biotech APIs market, by expression system, is dominated by mammalian expression systems owing to their ability to achieve the highest level of post-translational modifications and efficient protein folding, which makes them suitable for human use.

Segmentation

The global active pharmaceutical ingredient market is segmented based on type of drug, type of manufacturer, type of synthesis, based on therapeutic application and region. Based on the type of drug, the APIs market can be classified into two segments prescription drugs and over-the-counter (OTC) drugs Based on type of manufacturer, the APIs market can be divided into captive API manufacturers and merchant API manufacturers. Based on type of synthesis the market is bifurcated into Synthetic APIs Market, Biotech APIs Market. Based on therapeutic application the market is segmented into Communicable Diseases, Oncology, Diabetes, Cardiovascular Diseases, Pain Management, Respiratory Diseases, Other Therapeutic Applications.

Regional Analysis

The Global Active Pharmaceutical Ingredients Market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the global active pharmaceutical ingredients market. The region dominates the global active pharmaceutical ingredients market owing to the rising technological advancement in diagnostics coupled with the increasing incidences of chronic diseases and other neurological disorders.

Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are the presence of a large number of CMOs involved in manufacturing of APIs and the growing need to develop generic drugs.
Asia-Pacific is estimated to be the fastest-growing region in the Global Active Pharmaceutical Ingredients Market due to the presence of rapidly developing economies such as China, India, and South Korea that are emerging as major destinations for the outsourcing of drug manufacturing. Japan leads the Asia-Pacific active pharmaceutical ingredient market
The active pharmaceutical ingredients market in the Middle East & Africa is expected to grow due to the developing healthcare infrastructure and the continuously increasing demand for healthcare products.

TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Active Pharmaceutical Ingredient Market
Chapter 5. Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
5.1. Global Active Pharmaceutical Ingredient Market Share, By Types of Drug, 2015 - 2027 (USD Million)
5.1.1. Prescription Drugs
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Over-the-counter Drugs
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
6.1. Global Active Pharmaceutical Ingredient Share, By Type of Manufacturer, 2015 - 2027 (USD Million)
6.1.1. Captive API
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Merchant API
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
7.1. Global Active Pharmaceutical Ingredient Share, By Type of Synthesis, 2015 - 2027 (USD Million)
7.1.1. Synthetic API
7.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Biotic API
7.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Global Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
8.1. Global Active Pharmaceutical Ingredient Share, By Type of Synthesis, 2015 - 2027 (USD Million)
8.1.1. Communicable Diseases
8.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.2. Oncology
8.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.3. Diabetes
8.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.4. Cardiovascular Diseases
8.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.5. Pain Management
8.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.6. Respiratory Diseases
8.1.6.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.6.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
8.1.7. Others
8.1.7.1. Market Size and Projections, 2015 - 2027 (USD Million)
8.1.7.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 9. Global Active Pharmaceutical Ingredient Market Overview, By Geography, 2015 – 2027 (USD Million)
9.1. Global Active Pharmaceutical Ingredient Market Share, By Geography, 2015 - 2027 (USD Million)
9.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
9.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 10. North America Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. North America Global Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. North America Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
10.1.3. North America Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
10.1.4. North America Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
10.1.5. North America Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
10.1.6. North America Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.6.1. U.S. Global Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
10.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.6.1.2. U.S. Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
10.1.6.1.3. U.S. Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
10.1.6.1.4. U.S. Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
10.1.6.1.5. U.S. Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
10.1.6.2. Canada Global Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
10.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.6.2.2. Canada Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
10.1.6.2.3. Canada Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
10.1.6.2.4. Canada Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
10.1.6.2.5. Canada Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
10.1.6.3. Mexico Global Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
10.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.6.3.2. Mexico Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
10.1.6.3.3. Mexico Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
10.1.6.3.4. Mexico Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
10.1.6.3.5. Mexico Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
Chapter 11. Europe Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Europe Global Active Pharmaceutical Ingredient Market Overview, 2015 – 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Europe Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.3. Europe Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.4. Europe Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.5. Europe Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
11.1.6. Europe Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.6.1. Germany
11.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.1.2. Germany Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.6.1.3. Germany Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.6.1.4. Germany Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.6.1.5. Germany Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
11.1.6.2. France
11.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.2.2. France Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.6.2.3. France Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.6.2.4. France Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.6.2.5. France Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
11.1.6.3. UK
11.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.3.2. UK Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.6.3.3. UK Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.6.3.4. UK Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.6.3.5. UK Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
11.1.6.4. Italy
11.1.6.4.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.4.2. Italy Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.6.4.3. Italy Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.6.4.4. Italy Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.6.4.5. Italy Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
11.1.6.5. Spain
11.1.6.5.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.6.5.2. Spain Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.6.5.3. Spain Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.6.5.4. Spain Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.6.5.5. Spain Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
11.1.6.6. Rest of Europe
11.1.6.6.1. Market size and projections, 2015 – 2025
11.1.6.6.2. Rest of Europe Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
11.1.6.6.3. Rest of Europe Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
11.1.6.6.4. Rest of Europe Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
11.1.6.6.5. Rest of Europe Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
Chapter 12. Asia Pacific Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Asia Pacific Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
12.1.3. Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
12.1.4. Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
12.1.5. Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
12.1.6. Asia Pacific Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.6.1. India
12.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.1.2. India Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
12.1.6.1.3. India Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
12.1.6.1.4. India Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
12.1.6.1.5. India Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
12.1.6.2. China
12.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.2.2. China Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
12.1.6.2.3. China Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
12.1.6.2.4. China Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
12.1.6.2.5. China Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
12.1.6.3. Japan
12.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.3.2. Japan Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
12.1.6.3.3. Japan Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
12.1.6.3.4. Japan Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
12.1.6.3.5. Japan Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
12.1.6.4. South Korea
12.1.6.4.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.4.2. South Korea Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
12.1.6.4.3. South Korea Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
12.1.6.4.4. South Korea Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
12.1.6.4.5. South Korea Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
12.1.6.5. Rest of Asia Pacific
12.1.6.5.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.5.2. Rest of Asia Pacific Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
12.1.6.5.3. Rest of Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
12.1.6.5.4. Rest of Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
12.1.6.5.5. Rest of Asia Pacific Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
Chapter 13. Middle East & Africa Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. Middle East & Africa Global Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.2. Middle East & Africa Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
13.1.3. Middle East & Africa Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
13.1.4. Middle East & Africa Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
13.1.5. Middle East & Africa Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
13.1.6. Middle East & Africa Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1.6.1. GCC
13.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.6.1.2. GCC Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
13.1.6.1.3. GCC Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
13.1.6.1.4. GCC Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
13.1.6.1.5. GCC Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
13.1.6.2. South Africa
13.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.6.2.2. South Africa Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
13.1.6.2.3. South Africa Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
13.1.6.2.4. South Africa Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
13.1.6.2.5. South Africa Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
13.1.6.3. Rest of Middle East & Africa
13.1.6.3.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.6.3.2. Rest of Middle East & Africa Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
13.1.6.3.3. Rest of Middle East & Africa Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
13.1.6.3.4. Rest of Middle East & Africa Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
13.1.6.3.5. Rest of Middle East & Africa Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
Chapter 14. South America Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015 - 2027 (USD Million)
14.1. South America Global Active Pharmaceutical Ingredient Market Overview, 2015 - 2027 (USD Million)
14.1.1. Market size and projections, 2015 - 2027 (USD Million)
14.1.2. South America Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
14.1.3. South America Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
14.1.4. South America Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
14.1.5. South America Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
14.1.6. South America Global Active Pharmaceutical Ingredient Market Overview, By Countries, 2015- 2026 (USD Million)
14.1.6.1. Brazil
14.1.6.1.1. Market size and projections, 2015 - 2027 (USD Million)
14.1.6.1.2. Brazil Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
14.1.6.1.3. Brazil Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
14.1.6.1.4. Brazil Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
14.1.6.1.5. Brazil Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
14.1.6.2. Argentina
14.1.6.2.1. Market size and projections, 2015 - 2027 (USD Million)
14.1.6.2.2. Argentina Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
14.1.6.2.3. Argentina Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
14.1.6.2.4. Argentina Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
14.1.6.2.5. Argentina Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
14.1.6.3. Rest of South America
14.1.6.3.1. Market size and projections, 2015 – 2026
14.1.6.3.2. Rest of South America Global Active Pharmaceutical Ingredient Market Overview, By Types of Drug, 2015 - 2027 (USD Million)
14.1.6.3.3. Rest of South America Active Pharmaceutical Ingredient Market Overview, By Type of Manufacturer, 2015 - 2027 (USD Million)
14.1.6.3.4. Rest of South America Active Pharmaceutical Ingredient Market Overview, By Type of Synthesis, 2015 - 2027 (USD Million)
14.1.6.3.5. Rest of South America Active Pharmaceutical Ingredient Market Overview, By Therapeutic Application, 2015 - 2027 (USD Million)
Chapter 15. Competitive Landscape
15.1. Competitive environment, 2020
15.2. Strategic framework
15.2.1. Partnership/agreement
15.2.2. Expansion
15.2.3. Mergers & Acquisitions
15.2.4. New Types of Drug development
Chapter 16. Key Type of Manufacturer Analysis
16.1. Pfizer Inc.
16.1.1. Company overview
16.1.2. Financial performance
16.1.3. Types of Drug Benchmarking
16.1.4. Recent initiatives
16.1.5. SWOT analysis
16.2. Novartis AG
16.2.1. Company overview
16.2.2. Financial performance
16.2.3. Types of Drug Benchmarking
16.2.4. Recent initiatives
16.2.5. SWOT analysis
16.3. Sanofi
16.4. Boehringer Ingelheim.
16.5. Bristol-Myers Squibb
16.6. Teva Pharmaceutical Industries Ltd.
16.7. Eli Lily And Company
16.8. GlaxoSmithKline plc.
16.9. Merck & Co.
16.10. AbbVine Inc.
Chapter 17. Global Active Pharmaceutical Ingredient Market Cost Analysis
17.1. Global Active Pharmaceutical Ingredient Market Key Raw Materials Analysis
17.1.1. Key Raw Materials
17.1.2. Price Trend of Key Raw Materials
17.1.3. Key Suppliers of Raw Materials
17.1.4. Market Concentration Rate of Raw Materials
17.2. Proportion of Wing Cost Structure
17.2.1. Raw Materials
17.2.2. Labor Cost
17.2.3. Wing Expenses
17.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 18. Chain, Sourcing Strategy and Downstream Buyers
18.1. Global Active Pharmaceutical Ingredient Market Chain Analysis
18.2. Upstream Raw Materials Sourcing
18.3. Raw Materials Sources of Global Active Pharmaceutical Ingredient Market Major Manufacturers in 2019
18.4. Downstream Buyers
Chapter 19. Marketing Strategy Analysis, Distributors/Traders
19.1. Marketing Channel
19.1.1. Direct Marketing
19.1.2. Indirect Marketing
19.1.3. Marketing Channel Development Trend
19.2. Market Positioning
19.2.1. Pricing Strategy
19.2.2. Brand Strategy
19.2.3. Target Electrical Damage
19.3. Distributors/Traders List
Chapter 20. Market Effect Factors Analysis
20.1. Types of Drug Progress/Risk
20.1.1. Substitutes Threat
20.1.2. Types of Drug Progress in Related Industry
20.2. Oncology Needs/Customer Preference Change
20.3. Economic/Political Environmental Change
Chapter 21. Future Outlook of the Market
Disclaimer

List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Active Pharmaceutical Ingredient Market share, by Types of Drug, 2020 & 2027 (%)
10. Global Active Pharmaceutical Ingredient Market share, by Types of Drug 2020 & 2027 (USD Million)
11. Global Active Pharmaceutical Ingredient Market share, by Prescription Drugs, by Types of Drug, 2020 & 2027 (USD Million)
12. Global Active Pharmaceutical Ingredient Market share, by Over-the-counter Drugs, by Types of Drug, 2020 & 2027 (USD Million)
13. Global Active Pharmaceutical Ingredient Market share, by Type of Manufacturer, 2020 & 2027 (%)
14. Global Active Pharmaceutical Ingredient Market share, by Captive API, by Type of Manufacturer, 2020 & 2027 (USD Million)
15. Global Active Pharmaceutical Ingredient Market share, by Merchant API, by Type of Manufacturer, 2020 & 2027 (USD Million)
16. Global Active Pharmaceutical Ingredient Market share, by Type of Synthesis, 2020 & 2027 (%)
17. Global Active Pharmaceutical Ingredient Market share, by Synthetic API, by Type of Synthesis, 2020 & 2027 (USD Million)
18. Global Active Pharmaceutical Ingredient Market share, by Biotic API, by Type of Synthesis, 2020 & 2027 (USD Million)
19. Global Active Pharmaceutical Ingredient Market share, by Therapeutic Application, 2020 & 2027 (%)
20. Global Active Pharmaceutical Ingredient Market share, by Communicable Diseases, by Therapeutic Application, 2020 & 2027 (USD Million)
21. Global Active Pharmaceutical Ingredient Market share, by Oncology, by Therapeutic Application, 2020 & 2027 (USD Million)
22. Global Active Pharmaceutical Ingredient Market share, by Diabetes, by Therapeutic Application, 2020 & 2027 (USD Million)
23. Global Active Pharmaceutical Ingredient Market share, by Cardiovascular Diseases, by Therapeutic Application, 2020 & 2027 (USD Million)
24. Global Active Pharmaceutical Ingredient Market share, by region, 2020 - 2027(%)
25. Global Active Pharmaceutical Ingredient Market share, by region, 2019 - 2027(USD Million)
26. North America Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
27. North America Global Active Pharmaceutical Ingredient Market share, by Countries, 2020 & 2027 (%)
28. U.S. Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
29. Canada Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
30. Europe Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
31. Europe Global Active Pharmaceutical Ingredient Market share, by Countries, 2020 & 2027 (%)
32. Spain Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
33. UK Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
34. Italy Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
35. Germany Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
36. France Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
37. Rest of Europe Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
38. Asia-Pacific Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
39. Asia-Pacific Global Active Pharmaceutical Ingredient Market share, by Countries, 2020 & 2027 (%)
40. China Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
41. India Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
42. Australia Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
43. Japan Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
44. Rest of Asia-Pacific Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
45. Middle East & Africa Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
46. Middle East & Africa Global Active Pharmaceutical Ingredient Market share, by Countries, 2020 & 2027 (%)
47. GCC Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
48. South Africa Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
49. Rest of Middle East & Africa Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
50. South America Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
51. Brazil Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
52. Mexico Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
53. Argentina Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)
54. Rest Of South America Global Active Pharmaceutical Ingredient Market, 2020 - 2027(USD Million)

List of Tables

1. Impact of Market drivers
2. Impact of Market restraints
3. Global Active Pharmaceutical Ingredient Market, 2020-2027 (USD Million)
4. Active Pharmaceutical Ingredient requirement, by country, 2020-2027, (USD Million)
5. North America Active Pharmaceutical Ingredient Market, by Types of Drug, 2020-2027 (USD Million)
6. North America Active Pharmaceutical Ingredient Market, by Type of Manufacturer, 2020-2027 (USD Million)
7. North America Active Pharmaceutical Ingredient Market, by Type of Synthesis, 2020-2027 (USD Million)
8. North America Active Pharmaceutical Ingredient Market, by Therapeutic Application, 2020-2027 (USD Million)
9. Europe Active Pharmaceutical Ingredient Market, by Types of Drug, 2020-2027 (USD Million)
10. Europe Active Pharmaceutical Ingredient Market, by Type of Manufacturer, 2020-2027 (USD Million)
11. Europe Active Pharmaceutical Ingredient Market, by Type of Synthesis, 2020-2027 (USD Million)
12. Europe Active Pharmaceutical Ingredient Market, by Therapeutic Application, 2020-2027 (USD Million)
13. Asia Pacific Active Pharmaceutical Ingredient Market, by Types of Drug, 2020-2027 (USD Million)
14. Asia Pacific Active Pharmaceutical Ingredient Market, by Type of Manufacturer, 2020-2027 (USD Million)
15. Asia Pacific Active Pharmaceutical Ingredient Market, by Type of Synthesis, 2020-2027 (USD Million)
16. Asia Pacific Active Pharmaceutical Ingredient Market, by Therapeutic Application, 2020-2027 (USD Million)
17. Middle East & Africa Global Active Pharmaceutical Ingredient Market, by Types of Drug, 2020-2027 (USD Million)
18. Middle East & Africa Active Pharmaceutical Ingredient Market, by Type of Manufacturer, 2020-2027 (USD Million)
19. Middle East & Africa Active Pharmaceutical Ingredient Market, by Type of Synthesis, 2020-2027 (USD Million)
20. Middle East & Africa Active Pharmaceutical Ingredient Market, by Therapeutic Application, 2020-2027 (USD Million)
21. South America Active Pharmaceutical Ingredient Market, by Types of Drug, 2020-2027 (USD Million)
22. South America Active Pharmaceutical Ingredient Market, by Type of Manufacturer, 2020-2027 (USD Million)
23. South America Active Pharmaceutical Ingredient Market, by Type of Synthesis, 2020-2027 (USD Million)
24. South America Active Pharmaceutical Ingredient Market, by Therapeutic Application, 2020-2027 (USD Million)
25. Global Active Pharmaceutical Ingredient Market, Company Market Share, 2018 (%)
26. HEXAGON AB: Product Benchmarking
27. HEXAGON AB: Financial Performance
28. Novartis AG: Product Benchmarking
29. Novartis AG: Financial Performance
30. Sanofi: Product Benchmarking
31. Sanofi: Financial Performance
32. BOEHRINGER INGELHEIM.: Product Benchmarking
33. BOEHRINGER INGELHEIM.: Financial Performance
34. BRISTOL-MYERS SQUIBB: Product Benchmarking
35. BRISTOL-MYERS SQUIBB: Financial Performance

The Leading Key Players in Active Pharmaceutical Ingredient Market

Pfizer Inc. (US)
Novartis AG (Switzerland)
Sanofi (France)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Eli Lilly and Company (US)
GlaxoSmithKline plc (UK)
Merck & Co. Inc. (US)
AbbVie Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
AstraZeneca plc (UK).